- 4-Chloro-N-[1-(2-phenylethyl)piperidin-2-ylidene]benzene-1-sulfonamide
- 4-Chloro-N-(1-(2-phenylethyl)piperidin-2-ylidene]benzenesulfonamide
Knaus, EE; Warren, BK; Ondrus, TA. Analgesic substituted piperidylidene-2-sulfon(cyan)amide derivatives Patent US 4468403, 28 Aug 1984. 765 kB.
Huang, X; Che, T; Mangano, T; Rouzic, VL; Pan, Y; Majumdar, S; Cameron, M; Bauman, M; Pasternak, G; Roth, BL. Pharmacology of W-18 and W-15 bioRxiv, 24 Jul 2016, 065623. 2.2 MB. https://doi.org/10.1101/065623
EMCDDA. New drugs in Europe, 2013, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2014. 311 kB.
Sommerfeld-Klatta, K; Teżyk, A; Geppert, B. Toxicological analysis of new opioids In Chromatographic Techniques in the Forensic Analysis of Designer Drugs; Kowalska, T; Sajewicz, M; Sherma, J, Eds., CRC Press, Taylor & Francis Group, 1 Jan 2018; pp 391–417. 746 kB.
Huang, X; Che, T; Mangano, TJ; Rouzic, VL; Pan, Y; Majumdar, S; Cameron, MD; Baumann, MH; Pasternak, GW; Roth, BL. Fentanyl-related designer drugs W-18 and W-15 lack appreciable opioid activity in vitro and in vivo JCI Insight, 19 Jan 2018, 2 (22), n/a. 1.5 MB. https://doi.org/10.1172/jci.insight.97222 #W-15